BRITISH COLUMBIA, CANADA, September 18 /CNW/ - InNexus Biotechnology Inc.
(OTCBB: IXSBF, TSX: IXS), a drug development company commercializing the next
generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) technology, is pleased to announce that Jeff Morhet, Chairman and
CEO, will be a guest speaker on BNN - Business News Network's Power Breakfast
segment, which highlights top officials of important and powerful companies in
Canadian and U.S. business.
During the month of September, BNN's Power Breakfast will highlight
profitable and interesting companies on the TSX Venture Exchange. The segment
will air Wednesday, September 26, on the morning show, The Street - with Linda
Sims, and will run at 8:50 a.m. ET.
BNN - Business News Network is Canada's only television service devoted
exclusively to business, finance and the markets. It is available throughout
Canada on cable, satellite and wireless systems and is wholly owned by CTV
Inc., a division of CTVglobemedia.
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona, on the campus of Mayo Clinic, and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit www.ixsbio.com.
This news release contains certain "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995,
including, without limitation, statements regarding future drug development
activities or anticipated products, anticipated future revenues, benefits or
advantages, and the future plans and objectives of the Company, that involve
inherent risks and uncertainties and are subject to factors, many of which are
beyond the Company's control, that may cause actual results or performance to
differ materially from those currently anticipated in such statements.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: InNexus Biotechnology Inc. Jeff Morhet,
480-862-7500 www.ixsbio.com or The Investor Relations Group Investor
Relations: Christine Berni/Joe Triunfo, 212-825-3210
email@example.com firstname.lastname@example.org Media:
Janet Vasquez email@example.com